snapIoT Inc., a San Diego-based company, announces Automated AI-powered IRB Packaging and UAT Reporting feature to assemble all patient-facing visual assets and expedite the submission process for IRB and ethics approvals. Traditionally, this time-consuming process of IRB and ethics packaging is prone to human error and performed manually at the end of app development stages.
snapClinical™’s AI-powered Automated Documentation Engine creates key patient facing documentation assets for IRB Package setup and submission as well as UAT Reporting. With one single click, an AI-powered automation engine will: execute the app, go through all screens and generate screenshots, traverse all protocol flows and gather forms data information and auto-generate the needed materials within a single report. Annotations can be documented and exported to various file formats for further editing and processing. Pharma and CRO companies now have a faster, more efficient, and reliable method to help launch digitally enabled clinical trials.
“We have worked very closely with an early stage User Group comprised of many of the Top 10 Pharmaceutical and CRO companies as well as several IRB and Ethics SME’s to rapidly deploy this modern feature. Our Automated AI-powered IRB Packaging and UAT Reporting feature achieves the objectives of a better streamlined process to reduce time, costs and human error,” said Isaac Eteminan, CEO of snapIoT.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.